Alvotech (HAM:Z45) Current Deferred Revenue: €15.8 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HAM:Z45 Alvotech HAM:Z45
47 GF Score
Price €4.08
GF Value €10.68
Valuation Possible Value Trap
! 9 Warning Signs
View Full Analysis

What is Alvotech Current Deferred Revenue?

Alvotech HAM:Z45 +0.74% 47 Current Deferred Revenue is €15.8 Mil as of Jun. 2026. GuruFocus rates HAM:Z45 with a GF Score™ of 47/100 and a GF Value™ of €10.68 (Possible Value Trap). The stock has 9 warning signs investors should review.

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Alvotech's current deferred revenue for the quarter that ended in Jun. 2026 was €15.8 Mil.

Alvotech Current Deferred Revenue Related Terms

Alvotech Current Deferred Revenue Historical Data

* Premium members only.

The historical data trend for Alvotech's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alvotech Current Deferred Revenue Chart

Alvotech Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Deferred Revenue
Get a 7-Day Free Trial 26.28 34.85 54.27 15.26 25.93

Alvotech Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Current Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 52.31 42.53 25.93 8.26 15.79
HAM:Z45
47GF Score
Alvotech HAM:Z45
Current Deferred Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Current Deferred Revenue of €15.8 Mil mean?
Alvotech (HAM:Z45) has a Current Deferred Revenue of €15.8 Mil as of Jun. 2026. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Alvotech and its competitors.
Is Alvotech's Current Deferred Revenue too high?
Alvotech's current Current Deferred Revenue is €15.8 Mil. Overall, Alvotech has a GF Score™ of 47/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Alvotech's Current Deferred Revenue compare to ETON and ANIP?
Alvotech's Current Deferred Revenue of €15.8 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Deferred Revenue for a Drug Manufacturers company?
A good Current Deferred Revenue depends on the Drug Manufacturers industry context. However, Current Deferred Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Deferred Revenue mean?
A high Current Deferred Revenue can signal that a stock is expensive relative to its fundamentals. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Alvotech and its competitors. Alvotech's current Current Deferred Revenue is €15.8 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alvotech stock overvalued right now?
Based on GuruFocus' analysis, Alvotech (HAM:Z45) is currently considered Possible Value Trap. The stock's GF Value™ is €10.68, compared to a current price of €4.08 — trading 61.8% below its estimated fair value. The current Current Deferred Revenue is €15.8 Mil. Alvotech's overall GF Score™ is 47/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Deferred Revenue calculated?
Current Deferred Revenue is calculated from a company's financial statements. For Alvotech (HAM:Z45), the current Current Deferred Revenue is €15.8 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Alvotech (HAM:Z45) Overvalued in 2026?

Based on GuruFocus' analysis, Alvotech stock appears to be undervalued. The current stock price of €4.08 is trading 61.8% below its estimated GF Value™ of €10.68. GuruFocus considers Alvotech to be Possible Value Trap.

Key valuation signals for HAM:Z45:

  • Current Deferred Revenue: €15.8 Mil
  • GF Value™: €10.68 vs. price of €4.08 (61.8% below fair value)
  • GF Score™: 47/100 with 9 warning signs

No single metric tells the full story. See the HAM:Z45 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Alvotech Business Description

Other Exchanges ALVO:USAALVO:Iceland
Address 9, rue de Bitbourg, Luxembourg, LUX, L-1273
Alvotech is a biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients globally. Its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases. The company's commercialized products incldue AVT02, AVT03, AVT04, AVT05, and AVT06. Its pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, and cancer. Geographically, the company generates the majority of revenue from Europe, and the rest from the USA and the rest of the world.
47GF Score

Get the complete analysis for HAM:Z45

Current Deferred Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.08
Price
€10.68
GF Value